Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) EBITDA Margin (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed EBITDA Margin for 2 consecutive years, with 75.7% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 83515.0% to 75.7% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 80.05% through Dec 2025, up 83800.0% year-over-year, with the annual reading at 80.05% for FY2025, 83800.0% up from the prior year.
  • EBITDA Margin hit 75.7% in Q4 2025 for Xilio Therapeutics, up from 85.42% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 75.7% in Q4 2025 to a low of 759.45% in Q4 2024.